Bortezomib induces osteoblast differentiation via Wnt-independent activation of  -catenin/TCF signaling

Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth

(2008) Y.-W. Qiang et al.   BLOOD

The role of Dickkopf-1 in bone development, homeostasis, and disease

(2008) J. J. Pinzone et al.   BLOOD

Modulation of Dickkopf-1 Attenuates Glucocorticoid Induction of Osteoblast Apoptosis, Adipocytic Differentiation, and Bone Mass Loss

(2008) Feng-Sheng Wang et al.   ENDOCRINOLOGY

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma

(2008) Martin Kaiser et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

R-spondin1 synergizes with Wnt3A in inducing osteoblast differentiation and osteoprotegerin expression

(2008) Wenyan Lu et al.   FEBS LETTERS

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

(2008) E Terpos et al.   LEUKEMIA